Flulaval Quadrivalent Influenza Description

Flulaval Quadrivalent is a quadrivalent, split-virion, inactivated influenza virus vaccine prepared from virus propagated in the allantoic cavity of embryonated hens’ eggs. Each of the influenza viruses is produced and purified separately. The virus is inactivated with ultraviolet light treatment followed by formaldehyde treatment, purified by centrifugation, and disrupted with sodium deoxycholate.

Flulaval Quadrivalent contains thimerosal.

Flulaval for 2020-2021, quadrivalent (four-component) egg-based vaccines are recommended to contain:

A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus (updated)

A/Hong Kong/2671/2019 (H3N2)-like virus (updated)

B/Washington/02/2019 (B/Victoria lineage)-like virus (updated)

B/Phuket/3073/2013-like (Yamagata lineage) virus.

Flulaval Quadrivalent Influenza Indication

Flulaval Quadrivalent is indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Flulaval Quadrivalent Influenza Dosage

Flulaval Quadrivalent is approved for use in persons aged 6 months and older.

Flulaval Quadrivalent is administered as an intramuscular injection.

For detailed dosage information visit GSK.

Flulaval Quadrivalent Influenza News

July 28, 2020 - GSK begins shipping record number of its influenza vaccine doses for 2020-21 season for US market. FLULAVAL QUADRIVALENT will be available in a 0.5mL, single-dose, pre-filled syringe, and indicated for patients 6 months and older in line with CDC recommendations.